AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for a variety of therapeutic applications. Partnered with leading global biopharmaceutical companies, the company continues to pursue collaborations in inflammation, metabolic diseases, oncology, and other therapeutic areas, in addition to advancing its internal pipeline. The company’s technology enables the development of inexpensive, durable, highly specific proteins with differentiated and enhanced therapeutic properties and with the potential for multiple routes of delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.